Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Ravn Landtblom, A
Dickman, P W
Kristinsson, S Y
Andersson, T M-L
MetadataShow full item record
CitationHultcrantz M, Ravn Landtblom A, Andréasson B, et al. Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden. J Intern Med. 2020;287(4):448‐454. doi:10.1111/joim.13019
AbstractBackground: The reported incidence of Philadelphia-negative myeloproliferative neoplasms (MPNs) differs substantially between previous reports, likely due to true regional differences in incidence and/or variations in the quality and coverage of the cancer registers. Objective: We therefore assessed MPN incidence in Sweden during recent years using prospectively collected information captured in Swedish health registers. Methods: Patients with MPNs were identified through the Swedish Cancer Register and Swedish Blood Cancer Register between 2000 and 2014. Information on the Swedish population was obtained from the Human Mortality Database. Crude and age-standardized incidence rates of MPNs with 95% confidence intervals (CIs) were calculated. Results: A total of 6281 MPN cases were reported to the Swedish Cancer Register and Swedish Blood Cancer Register during 2000-2014. The age-standardized, to the Swedish population in 2000, incidence for all MPNs was 4.45 (95% confidence interval [CI] 4.34-4.56)/100 000 person-years. The age-standardized incidence for polycythemia vera was 1.48 (1.42-1.54), for essential thrombocythemia 1.60 (1.53-1.66) and for primary myelofibrosis 0.52 (0.48-0.56)/100 000 person-years, respectively. The incidence rate of MPNs was substantially higher in the older compared to the younger age groups. The incidence increased during the study period, likely to do better reporting and increasing age of the general population. Conclusion: The reported MPN incidences in our study, which were in the higher interval of previously published studies, are likely more accurate compared to previous reports due to the population-based setting and high level of coverage in the Swedish Cancer and Blood Cancer Registers.
DescriptionTo access publisher's full text version of this article click on the hyperlink below
Rights© 2020 The Association for the Publication of the Journal of Internal Medicine.
- Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada.
- Authors: Heppner J, Nguyen LT, Guo M, Naugler C, Rashid-Kolvear F
- Issue date: 2019 May 24
- Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
- Authors: Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Björkholm M
- Issue date: 2008 Sep 15
- Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union.
- Authors: Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA
- Issue date: 2014 Apr
- Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
- Authors: Deadmond MA, Smith-Gagen JA
- Issue date: 2015 Dec
- MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria.
- Authors: Yassin MA, Taher A, Mathews V, Hou HA, Shamsi T, Tuğlular TF, Xiao Z, Kim SJ, Depei W, Li J, Rippin G, Sadek I, Siddiqui A, Wong RS
- Issue date: 2020 Jul